BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) can result from hepatitis C virus
(HCV)-related liver disease and is the fastest-growing cause of cancer-related death in the …

Background and Aims The prognostic ability of α-fetoprotein (AFP) for patients with
hepatocellular carcinoma (HCC) was examined by using different cutoff values. The optimal …

The prognostic impact of serum α-fetoprotein (AFP) level in patients with hepatocellular
carcinoma (HCC) is controversial. This study aimed to investigate the predictive ability of …

Abstract α‑fetoprotein (AFP) is a tumor marker of hepatocellular carcinoma (HCC) and has
also been reported to reflect the effectiveness of long‑term low‑dose interferon (IFN) therapy …

Methods We enrolled 55 patients of HCV-related LC with HCC and 62 patients without HCC
as a case-control study were analyzed. The sensitivity and specificity were calculated and …

Background Noninvasive risk factors are required for predicting the development of
hepatocellular carcinoma (HCC) not only in patients with cirrhosis but also in those with …

BACKGROUND α‐Fetoprotein (AFP) is a biomarker commonly used in the management of
patients with hepatocellular carcinoma (HCC), although the possible determinants of its …

Abstract α-Fetoprotein (AFP) is frequently used as a diagnostic marker for hepatocellular
carcinoma (HCC). Most available data concerning AFP come from studies of patients with …

BACKGROUND/AIMS: Alpha-fetoprotein (AFP) has been useful in the diagnosis of
hepatocellular carcinoma (HCC) but lacks specificity. We assessed serum AFP among …

AIM: To explore the relationship between α-fetoprotein (AFP) and various clinicopathological
variables and different staging system of hepatocellular carcinoma (HCC) thoroughly …